Your browser is no longer supported. Please, upgrade your browser.
Settings
MEIP MEI Pharma, Inc. daily Stock Chart
MEIP [NASD]
MEI Pharma, Inc.
Index- P/E- EPS (ttm)-0.55 Insider Own0.78% Shs Outstand72.36M Perf Week-1.92%
Market Cap222.15M Forward P/E- EPS next Y-0.71 Insider Trans0.00% Shs Float70.60M Perf Month0.66%
Income-27.70M PEG- EPS next Q-0.17 Inst Own58.10% Short Float0.23% Perf Quarter14.55%
Sales3.50M P/S63.47 EPS this Y40.20% Inst Trans-0.08% Short Ratio0.93 Perf Half Y-23.63%
Book/sh0.75 P/B4.09 EPS next Y-22.40% ROA-33.30% Target Price8.19 Perf Year42.79%
Cash/sh1.29 P/C2.38 EPS next 5Y-0.10% ROE-62.80% 52W Range1.82 - 5.14 Perf YTD16.29%
Dividend- P/FCF- EPS past 5Y2.60% ROI-56.60% 52W High-40.27% Beta1.94
Dividend %- Quick Ratio8.80 Sales past 5Y- Gross Margin-14.70% 52W Low68.68% ATR0.14
Employees32 Current Ratio8.80 Sales Q/Q400.00% Oper. Margin- RSI (14)50.87 Volatility5.86% 4.39%
OptionableYes Debt/Eq0.00 EPS Q/Q204.10% Profit Margin- Rel Volume1.16 Prev Close3.00
ShortableYes LT Debt/Eq0.00 EarningsMay 08 AMC Payout- Avg Volume173.90K Price3.07
Recom1.50 SMA20-1.16% SMA501.63% SMA200-7.73% Volume202,772 Change2.33%
Dec-20-18Initiated H.C. Wainwright Buy $10
Dec-20-18Initiated H.C. Wainwright Buy
Jul-27-18Upgrade Stifel Hold → Buy $2.50 → $7
Jul-13-18Initiated SunTrust Buy $12
Apr-18-16Reiterated Wedbush Neutral $3 → $2
Mar-23-15Downgrade ROTH Capital Buy → Neutral $14 → $2.50
Dec-18-14Reiterated ROTH Capital Buy $22 → $14
Oct-16-14Reiterated ROTH Capital Buy $20 → $22
Jul-08-14Resumed Brean Capital Buy $16
Oct-22-13Reiterated Stifel Buy $11 → $15
Apr-15-13Initiated Stifel Buy $11
Apr-12-19 04:52PM  2 Biotech Stock Picks From Legendary Investor Joseph Edelman GuruFocus.com
Apr-02-19 08:00AM  MEI Pharma to Present at the 18th Annual Needham Healthcare Conference PR Newswire
Mar-12-19 08:00AM  MEI Pharma to Present at the 29th Annual Oppenheimer Healthcare Conference PR Newswire
Feb-28-19 10:39AM  A Holistic Look At MEI Pharma, Inc. (NASDAQ:MEIP) Simply Wall St.
Feb-07-19 04:05PM  MEI Pharma Reports Second Quarter Fiscal Year 2019 Results and Operational Highlights PR Newswire
10:31AM  MEI Pharma (MEIP) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release Zacks
Jan-21-19 11:01AM  What Percentage Of MEI Pharma, Inc. (NASDAQ:MEIP) Shares Do Insiders Own? Simply Wall St.
Dec-03-18 01:32PM  Phase 2 Interim Data Evaluating the Combination of Pracinostat and Azacitidine in Patients with Myelodysplastic Syndrome Presented at the 2018 American Society of Hematology Annual Meeting PR Newswire -5.90%
Dec-02-18 12:00PM  MEI Pharma Presents Clinical Data from Ongoing Phase 1b Study of ME-401 in Patients with Indolent B-Cell Malignancies at the 2018 American Society of Hematology Annual Meeting PR Newswire
Dec-01-18 12:00PM  MEI Pharma Presents Preclinical Data Demonstrating Voruciclib Synergistically Induces Apoptosis in Combination with Venetoclax in Acute Myeloid Leukemia Cells at the 2018 American Society of Hematology Annual Meeting PR Newswire
Nov-30-18 01:21PM  Is MEI Pharma Incs (NASDAQ:MEIP) CEO Paid At A Competitive Rate? Simply Wall St.
Nov-19-18 08:10AM  Market Trends Toward New Normal in Lightbridge, MEI Pharma, Good Times Restaurants, Lilis Energy, Microbot Medical, and S&W Seed Emerging Consolidated Expectations, Analyst Ratings GlobeNewswire -9.90%
Nov-12-18 05:45AM  MEI Pharma Sees Hammer Chart Pattern: Time to Buy? Zacks -6.10%
Nov-08-18 04:00PM  MEI Pharma Reports First Quarter Fiscal Year 2019 Results and Operational Highlights PR Newswire
Nov-07-18 10:30AM  Will MEI Pharma (MEIP) Report Negative Earnings Next Week? What You Should Know Zacks
Nov-06-18 08:00AM  MEI Pharma To Present at Stifel 2018 Healthcare Conference PR Newswire
Nov-05-18 08:00AM  MEI Pharma and Kyowa Hakko Kirin Announce License Agreement to Develop and Commercialize ME-401 in Japan PR Newswire
Nov-02-18 08:37AM  Implied Volatility Surging for MEI Pharma (MEIP) Stock Options Zacks
Nov-01-18 09:00AM  MEI Pharma to Present Clinical Data from Three Oncology Programs at the 2018 American Society of Hematology (ASH) Annual Meeting PR Newswire
Oct-11-18 06:42AM  BRIEF-MEI Pharma And Beigene Announce Clinical Collaboration Reuters +8.71%
06:00AM  MEI Pharma and BeiGene Announce Clinical Collaboration to Evaluate ME-401 in Combination with Zanubrutinib in Patients with B-Cell Malignancies PR Newswire
Sep-20-18 11:55AM  What does MEI Pharma Incs (NASDAQ:MEIP) Balance Sheet Tell Us About Its Future? Simply Wall St.
Sep-10-18 03:21AM  Edited Transcript of MEIP earnings conference call or presentation 30-Aug-18 9:00pm GMT Thomson Reuters StreetEvents
Aug-31-18 08:00AM  Today's Research Reports on Trending Tickers: Sangamo Therapeutics and MEI Pharma ACCESSWIRE -6.90%
Aug-30-18 04:05PM  MEI Pharma Reports Fiscal Year 2018 Results and Operational Highlights PR Newswire +5.65%
03:00PM  MEI Pharma, Inc. to Host Earnings Call ACCESSWIRE
Aug-29-18 08:38AM  Should You Buy MEI Pharma (MEIP) Ahead of Earnings? Zacks
08:00AM  MEI Pharma To Present at Wells Fargo Securities 2018 Healthcare Conference PR Newswire
Aug-23-18 08:00AM  MEI Pharma to Release 2018 Fiscal Year End Financial Results and Provide Corporate Update on August 30, 2018 PR Newswire
Jul-30-18 07:10AM  Initiating Free Research Reports on Synergy Pharma and Three Other Drug Makers Equities ACCESSWIRE
Jul-27-18 10:29AM  Stifel Doubles Down On MEI Pharma, Considers ME-401 'Best-In-Class' Benzinga +6.55%
Jul-16-18 08:00AM  MEI Pharma Promotes David M. Urso to Chief Operating Officer PR Newswire
Jun-28-18 07:35AM  Initiating Free Research Reports on Canopy Growth and Three Other Drug Makers Equities ACCESSWIRE
Jun-15-18 08:00AM  MEI Pharma Presents Clinical Data on ME-401 at the European Hematology Association Congress PR Newswire
Jun-11-18 08:00AM  MEI Pharma, Partnerships, Well-Funded Clinical Programs and Promising Clinical Data Driving Oncology Research GlobeNewswire
Jun-04-18 08:01AM  MEI Pharma Presents Phase 1b Clinical Data for ME-401 in Patients with Indolent B-Cell Malignancies at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting PR Newswire
08:00AM  MEI Pharma Presents Clinical Data for ME-344 in HER2 Negative Breast Cancer Patients at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting PR Newswire
May-31-18 08:30AM  MEI Pharma and Helsinn Group Announce Successful Interim Analysis of Pracinostat/Azacitidine Phase 2 Combination Study in Higher Risk Myelodysplastic Syndrome (MDS) Patients PR Newswire
May-16-18 05:00PM  MEI Pharma to Present Clinical Data at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting PR Newswire
May-14-18 08:00AM  MEI Pharma Announces $75 Million Private Placement PR Newswire +13.45%
May-09-18 08:30AM  MEI Pharma Reports Third Quarter Fiscal Year 2018 Results PR Newswire
Mar-14-18 08:00AM  MEI Pharma To Present at Two Upcoming Investor Conferences PR Newswire
Feb-26-18 08:00AM  MEI Pharma Appoints Industry Veteran Frederick W. Driscoll to its Board of Directors PR Newswire
Feb-13-18 08:00AM  MEI Pharma Interim Data Review Supports Continuation of Clinical Study Evaluating ME-344 in Patients with Breast Cancer PR Newswire
Feb-08-18 08:00AM  MEI Pharma Reports Second Quarter Fiscal Year 2018 Results PR Newswire -6.44%
Jan-11-18 03:00AM  Helsinn Group and MEI Pharma Announce that Pracinostat has Received Orphan Drug Designation from the European Medicines Agency for the Treatment of Acute Myeloid Leukemia (AML) PR Newswire +6.47%
Jan-08-18 09:00AM  MEI Pharma Announces FDA Clearance of Investigational New Drug Application for CDK Inhibitor Voruciclib PR Newswire
Dec-25-17 12:08PM  ETFs with exposure to MEI Pharma, Inc. : December 25, 2017 Capital Cube
Dec-21-17 09:00AM  MEI Pharma Announces Study of Clinical Stage Oral CDK Inhibitor Voruciclib Published in Nature Scientific Reports PR Newswire -5.45%
Dec-12-17 01:37PM  ETFs with exposure to MEI Pharma, Inc. : December 12, 2017 Capital Cube
Nov-22-17 09:00AM  MEI Pharma to Host Annual Meeting of Stockholders PR Newswire +10.80%
Nov-20-17 12:52PM  ETFs with exposure to MEI Pharma, Inc. : November 20, 2017 Capital Cube -8.19%
Nov-10-17 12:41PM  ETFs with exposure to MEI Pharma, Inc. : November 10, 2017 Capital Cube
Nov-09-17 09:37AM  MEI Pharma, Inc. :MEIP-US: Earnings Analysis: Q1, 2018 By the Numbers : November 9, 2017 Capital Cube
Nov-08-17 09:00AM  MEI Pharma Reports First Quarter Fiscal Year 2018 Results PR Newswire -8.56%
Nov-07-17 09:00AM  MEI Pharma to Present at Stifel 2017 Healthcare Conference PR Newswire
Oct-16-17 08:36AM  Aurinia Pharmaceuticals (AUPH) Looks Good: Stock Adds 7.8% in Session Zacks
Oct-02-17 08:30AM  PTC Therapeutics, Inc. (PTCT) in Focus: Stock Moves 14.6% Higher Zacks
Sep-27-17 10:16AM  Edited Transcript of MEIP earnings conference call or presentation 5-Sep-17 1:00pm GMT Thomson Reuters StreetEvents
Sep-26-17 08:57AM  GlycoMimetics (GLYC) in Focus: Stock Moves 9.2% Higher Zacks
07:20AM  Earnings Review and Free Research Report: MEI Pharma Reported its Full Year FY17 Results ACCESSWIRE
Sep-19-17 09:00AM  MEI Pharma to Present at Cantor Fitzgerald Global Healthcare Conference PR Newswire
Sep-12-17 07:20AM  Featured Company News - Teva Pharmaceuticals Presents Outcome Measure Results from Phase-III Clinical Trials for the Potential of Fremanezumab to Treat Migraine Patients ACCESSWIRE
Sep-11-17 08:37AM  Zogenix, Inc. (ZGNX) Jumps: Stock Rises 5.2% Zacks
Sep-06-17 10:50AM  MEI Pharma-Presage Biosciences on License Deal for Voruciclib Zacks
Sep-05-17 04:05PM  MEI Pharma Announces Exclusive License Agreement with Presage Biosciences for Voruciclib, An Oral, Selective CDK Inhibitor PR Newswire +5.36%
08:30AM  MEI Pharma Reports Fiscal Year 2017 Results PR Newswire
Aug-31-17 09:00AM  MEI Pharma to Present at Two Upcoming Investor Conferences PR Newswire
Aug-29-17 09:00AM  MEI Pharma to Host Fiscal Year End Conference Call on September 5, 2017 PR Newswire
Aug-02-17 08:00AM  Helsinn Group and MEI Pharma Announce First Patient Dosed in Pivotal Phase 3 Study of Pracinostat and Azacitidine in Acute Myeloid Leukemia PR Newswire
Jul-07-17 08:30AM  MEI Pharma (MEIP) Worth a Look: Stock Rises 12% in Session Zacks
Jul-03-17 10:11AM  BioMarin Files BLA for Phenylketonuria Candidate Pegvaliase Zacks
Jun-29-17 10:49AM  Valeant's (VRX) NDA for Bowel Cleansing Drug Accepted by FDA Zacks
Jun-22-17 10:54AM  Shire (SHPG) Receives MAA Validation for Veyvondi by EMA Zacks
10:03AM  Indivor's Opioid Use Disorder Drug Meets Primary Endpoint Zacks
Jun-20-17 11:24AM  Horizon Pharma Gets Health Canada Approval for Procysbi Zacks
10:31AM  Seattle Genetics Halts Phase III Study on Leukemia Drug Zacks
Jun-16-17 04:22PM  Mallinckrodt Initiates Amyotrophic Lateral Sclerosis Study Zacks
10:53AM  Omeros (OMER) Hits New 52-Week High on Positive FDA Decision Zacks
Jun-14-17 10:27AM  Omeros (OMER) Lead Candidate Gets Breakthrough Designation Zacks +5.53%
09:09AM  Novo Nordisk (NVO) Presents Data for Type II Diabetes Drug Zacks
08:30AM  Helsinn Group and MEI Pharma Announce First Patient Dosed in Phase 2 Dose-Optimization Study of Pracinostat and Azacitidine in Myelodysplastic Syndrome PR Newswire
Jun-13-17 10:16AM  Seres Therapeutics' Stock Up as SER-109 Moves to Phase III Zacks +7.57%
10:03AM  Intercept (ICPT) Releases Data from Phase II Flint Trial Zacks
Jun-12-17 10:47AM  Alkermes Commences Phase III Study for Schizophrenia Drug Zacks
Jun-08-17 11:09AM  Mallinckrodt (MNK) Commences Phase III Study of StrataGraft Zacks -7.07%
Jun-06-17 06:08PM  Seattle Genetics Reports Updated Results on Cancer Drug Zacks
Jun-05-17 11:26AM  Radius (RDUS) Announces Positive Data on Breast Cancer Drug Zacks
09:00AM  Helsinn Group and MEI Pharma Report Correlation between Mutations in DNA Methylation Pathway and Clinical Response in Phase II Study of Pracinostat and Azacitidine in Acute Myeloid Leukemia PR Newswire
Jun-01-17 02:06PM  Novo Nordisk's (NVO) Drug Gets FDA Approval for Hemophilia B Zacks -8.00%
08:00AM  Today's Research Reports on Stocks to Watch: Catalyst Biosciences and MEI Pharma Accesswire
May-31-17 04:59PM  Ligand (LGND) Signs Licensing Deal with xCella Biosciences Zacks +5.63%
08:30AM  MEI Pharma Announces Pre-Specified Response Rate Exceeded in Dose-Escalation Study of ME-401 in Chronic Lymphocytic Leukemia and Follicular Lymphoma PR Newswire
May-30-17 11:19AM  4 Reasons Why You Should Add Bayer Stock to Your Portfolio Zacks
08:20AM  MEI Pharma (MEIP) Shows Strength: Stock Moves 7.6% Higher Zacks
May-25-17 10:42AM  Bristol-Myers' Opdivo Gets Priority Review for Liver Cancer Zacks +17.96%
May-24-17 11:08AM  Achaogen's Plazomicin Gets Breakthrough Therapy Designation Zacks
May-23-17 10:49AM  Catalyst Pharmaceuticals Focuses on Development of Firdapse Zacks
May-22-17 08:45AM  Calithera Biosciences (CALA) Jumps: Stock Moves 17% Higher Zacks
May-18-17 09:53AM  Vertex Ups Kalydeco Sales View as FDA Okays Label Expansion Zacks
MEI Pharma, Inc., a pharmaceutical company, focuses on the clinical development of novel therapies for the treatment of cancer. The company's clinical drug candidate includes Pracinostat, an oral available histone deacetylase inhibitor for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. Its clinical development portfolio also includes ME-401, an oral inhibitor of phosphatidylinositide 3-kinase delta for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia or follicular lymphoma; ME-344, an isoflavone-derived mitochondrial inhibitor for the treatment of HER2-negative breast cancer; and Voruciclib, an oral cyclin-dependent kinase inhibitor. The company has a license, development, and commercialization agreement with Helsinn Healthcare SA for the development, manufacture, and commercialization of Pracinostat; and license agreement with Presage Biosciences, Inc. to develop, manufacture, and commercialize Voruciclib, a clinical-stage, oral, and selective cyclin-dependent kinase inhibitor; and related compounds. It also has a clinical collaboration agreement with BeiGene, Ltd. to evaluate the safety and efficacy of ME-401 in combination with BeiGene's zanubrutinib, an investigational BTK inhibitor for the treatment of patients with B-cell malignancies. The company was formerly known as Marshall Edwards, Inc. and changed its name to MEI Pharma, Inc. in July 2012. MEI Pharma, Inc. was founded in 2000 and is based in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Urso David MChief Operating Officer & GCAug 07Sale3.589,50034,04424,106Aug 08 06:01 PM